{
    "info": {
        "nct_id": "NCT05429632",
        "official_title": "Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod As Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT",
        "inclusion_criteria": "* Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations\n* European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, [CRi] is also allowable\n* Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft\n* Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5\n* Planned use of CsA-based or TAC-based GvHD prophylaxis\n* age ≥ 18 years and ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
        "exclusion_criteria": "* Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis\n* Diagnosis of macular edema during screening\n* Cardiac/pulmonary/hepatic/renal dysfunction\n* Hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN); or total bilirubin > 1.5 mg/dL\n* Renal dysfunction with estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5",
            "criterions": [
                {
                    "exact_snippets": "Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5",
                    "criterion": "Transplant Conditioning Score (TCI)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 75 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 75 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 75,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, [CRi] is also allowable",
            "criterions": [
                {
                    "exact_snippets": "European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1",
                    "criterion": "acute myeloid leukemia (AML) risk group and remission status",
                    "requirements": [
                        {
                            "requirement_type": "risk group",
                            "expected_value": [
                                "high-risk",
                                "intermediate-risk"
                            ]
                        },
                        {
                            "requirement_type": "remission status",
                            "expected_value": "CR1"
                        }
                    ]
                },
                {
                    "exact_snippets": "AML of any risk in CR2",
                    "criterion": "acute myeloid leukemia (AML) remission status",
                    "requirements": [
                        {
                            "requirement_type": "remission status",
                            "expected_value": "CR2"
                        }
                    ]
                },
                {
                    "exact_snippets": "[CRi] is also allowable",
                    "criterion": "acute myeloid leukemia (AML) remission status",
                    "requirements": [
                        {
                            "requirement_type": "remission status",
                            "expected_value": "CRi"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft",
            "criterions": [
                {
                    "exact_snippets": "Planned allogeneic HCT",
                    "criterion": "allogeneic hematopoietic cell transplantation (HCT)",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "from fully matched related or unrelated donor with no more than 1 antigen mismatch",
                    "criterion": "donor HLA matching",
                    "requirements": [
                        {
                            "requirement_type": "donor type",
                            "expected_value": [
                                "fully matched related",
                                "fully matched unrelated"
                            ]
                        },
                        {
                            "requirement_type": "antigen mismatch",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "antigen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "planned use of haploidentical donor using PBSC graft",
                    "criterion": "haploidentical donor with PBSC graft",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned use of CsA-based or TAC-based GvHD prophylaxis",
            "criterions": [
                {
                    "exact_snippets": "Planned use of CsA-based or TAC-based GvHD prophylaxis",
                    "criterion": "GvHD prophylaxis regimen",
                    "requirements": [
                        {
                            "requirement_type": "planned use",
                            "expected_value": [
                                "CsA-based",
                                "TAC-based"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* age ≥ 18 years and ≤ 75 years",
            "criterions": [
                {
                    "exact_snippets": "age ≥ 18 years and ≤ 75 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 75,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of AML (excluding acute promyelocytic leukemia)",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "subtype exclusion",
                            "expected_value": "acute promyelocytic leukemia"
                        }
                    ]
                },
                {
                    "exact_snippets": "according to the WHO 2022 classification of AML and related precursor neoplasm",
                    "criterion": "AML diagnosis classification",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "WHO 2022"
                        }
                    ]
                },
                {
                    "exact_snippets": "including AML with myelodysplasia-related gene mutations",
                    "criterion": "AML with myelodysplasia-related gene mutations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Cardiac/pulmonary/hepatic/renal dysfunction",
            "criterions": [
                {
                    "exact_snippets": "Cardiac ... dysfunction",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "dysfunction",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary ... dysfunction",
                    "criterion": "pulmonary function",
                    "requirements": [
                        {
                            "requirement_type": "dysfunction",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatic ... dysfunction",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "dysfunction",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "renal ... dysfunction",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "dysfunction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of macular edema during screening",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of macular edema during screening",
                    "criterion": "macular edema",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal dysfunction with estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Renal dysfunction with estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula",
                    "criterion": "estimated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 45,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation_method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis",
            "criterions": [
                {
                    "exact_snippets": "Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis",
                    "criterion": "use of anti-thymocyte globulin (ATG) for GvHD prophylaxis",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis",
                    "criterion": "use of alemtuzumab for GvHD prophylaxis",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis",
                    "criterion": "use of abatacept for GvHD prophylaxis",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN); or total bilirubin > 1.5 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... > 2.5 x upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ... > 2.5 x upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin > 1.5 mg/dL",
                    "criterion": "total bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}